[Antithrombotic therapy in the treatment of STEMI and NSTEMI patients]

Area of Science:

• Cardiology
• Interventional Cardiology
• Pharmacology

Context:

• The Croatian network for primary percutaneous coronary intervention (PCI) is expanding, increasing patient access to this life-saving procedure.
• Despite advancements, optimal antithrombotic therapy remains critical for therapeutic success in patients undergoing PCI.
• Significant portions of the Croatian population still lack access to primary PCI services.

Purpose:

• To review the current landscape of antithrombotic therapies in the context of primary PCI in Croatia.
• To highlight the established and emerging roles of various antithrombotic agents in managing acute coronary syndromes.
• To underscore the importance of comprehensive antithrombotic strategies for maximizing the benefits of primary PCI.

Summary:

• Primary PCI network expansion in Croatia allows more patients to receive timely treatment for acute myocardial infarction.
• Established antithrombotic agents like aspirin and thienopyridines (e.g., clopidogrel) are vital.
• Newer agents, including GP IIb/IIIa inhibitors and improved fibrinolytic therapies, are increasingly integrated into clinical practice, offering enhanced efficacy and safety profiles.
• The role of low-molecular-weight heparins requires further clarification within this therapeutic framework.

Impact:

• Improved patient outcomes and reduced mortality from acute coronary syndromes through optimized antithrombotic strategies.
• Enhanced clinical practice guidelines for antithrombotic therapy in interventional cardiology.
• Potential for wider adoption of advanced antithrombotic treatments, balancing efficacy with cost-effectiveness.